Results: 12
Safety and Effectiveness of Direct Oral Anticoagulants Versus Warfarin in Patients with Venous Thromboembolism using Real-World Data: A Systematic Review and Meta-Analysis.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 6, p. 823, doi. 10.1007/s40256-024-00677-x
- By:
- Publication type:
- Article
SGLT2 Inhibitor Prescribing in Cardiovascular-Kidney-Metabolic Syndrome.
- Published in:
- 2024
- By:
- Publication type:
- Letter
A Clinicians Guide to Recommending Common Cholesterol-Lowering Dietary Supplements.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 6, p. 719, doi. 10.1007/s40256-024-00681-1
- By:
- Publication type:
- Article
Acknowledgement to Referees.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 6, p. 703, doi. 10.1007/s40256-024-00696-8
- Publication type:
- Article
Impact of Newly Diagnosed Cancer on Bleeding Events in Patients with Atrial Fibrillation Treated with Direct Oral Anticoagulants.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 6, p. 813, doi. 10.1007/s40256-024-00676-y
- By:
- Publication type:
- Article
Differences in Healthcare Resource Use and Cost by Pharmacotherapy Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Real-World Analysis of Claims Data.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 6, p. 801, doi. 10.1007/s40256-024-00674-0
- By:
- Publication type:
- Article
SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 6, p. 707, doi. 10.1007/s40256-024-00673-1
- By:
- Publication type:
- Article
The Efficacy and Safety of Levosimendan in Patients with Advanced Heart Failure: An Updated Meta-Analysis of Randomized Controlled Trials.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 6, p. 775, doi. 10.1007/s40256-024-00675-z
- By:
- Publication type:
- Article
A Real‑World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 6, p. 791, doi. 10.1007/s40256-024-00672-2
- By:
- Publication type:
- Article
Dapagliflozin in Heart Failure: A Comprehensive Meta-analysis on Functional Capacity, Symptoms, and Safety Outcomes.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 6, p. 753, doi. 10.1007/s40256-024-00669-x
- By:
- Publication type:
- Article
Time Gained to Cardiovascular Disease by Intensive Lipid-Lowering Therapy: Results of Individual Placebo-Controlled Trials and Pooled Effects.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 6, p. 743, doi. 10.1007/s40256-024-00668-y
- By:
- Publication type:
- Article
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 6, p. 729, doi. 10.1007/s40256-024-00665-1
- By:
- Publication type:
- Article